spine anatomy

Dignify Therapeutics Receives NIH Award for Preclinical and Clinical Development of a Novel, On-Demand, Voiding Therapy

Dignify Therapeutics LLC, a pharmaceutical and medical device development company focused on restoring bladder and bowel control for people with spinal injury, multiple sclerosis, diabetes, and the elderly, was awarded the prestigious Blueprint Neurotherapeutics Network grant from the National Institutes of Health (NIH). This 4-year award provides over $4 million in funding to support preclinical and clinical development of the Company’s lead drug candidate, DTI-117, to treat bladder and bowel dysfunction. “This new award exemplifies the foresight of, and commitment from, the NIH to develop treatments for bladder and bowel dysfunction in people suffering from these conditions” said company President and Principal Investigator, Dr. Ed Burgard. “This award will provide funds for an IND submission and a subsequent clinical trial for DTI-117”. Read more.

Source: Dignify Therapeutics website, February 27, 2023

women friends

Behavioral Therapy Superior to Drugs Alone for Urinary Incontinence

Behavioral therapies relieve stress, urgency, and mixed urinary incontinence (UI) more effectively than drug monotherapies in nonpregnant women.  In a new systematic review and network meta-analysis (NMA) of 84 randomized trials published in theAnnals of Internal Medicine, most interventions including combination therapies improved or resolved women’s symptoms better than no treatment, whether sham or watchful waiting, Ethan Balk, MD, MPH, of Brown University in Providence, Rhode Island, and colleagues reported. Hormones and periurethral bulking agents appeared less than effective, however. Read more.

Source: Renal & Urology News, March 20, 2019

drugs for overactive bladder (OAB)

Urinary Incontinence: What Pharmacists Should Know

Urinary incontinence (UI), the involuntary leakage of urine, is a frequent and problematic chronic condition for many patients. An estimated 10 to 30% of men and women are affected nationally, though this may be underestimated due to underdiagnoses and undertreatment.1-3 Often, patients who suffer with UI symptoms will develop poor self-rated health, depression, and mobility disability.4,5 This comorbid disease state also presents a substantial financial burden; data from 2014 found that in the United States alone, an estimated $65.9 billion in direct and indirect costs were spent for UI treatment.3  Read more.

Source: Drug Topics, January 23, 2018

medical research

RDD Pharma Awarded CDMRP Grant for Clinical Drug for SCI Patients

RDD Pharma, a leader in developing treatments for anorectal disorders, announced today the Department of Defense office of the Congressionally Directed Medical Research Programs (CDMRP) has funded the Spinal Cord Injury Research Program (SCIRP) Translational Research Award – Clinical Trial application.  The grant of $1.28M will enable initial U.S. clinical development of RDD-0315 for fecal incontinence in spinal cord injury patients including preparations for and conducting of a Phase 1 study in healthy volunteers to assess acute tolerance and PK.  “We are pleased the CDMRP recognized the clinically significant benefit that RDD-0315 may offer spinal cord injury patients,” stated Jason Laufer, Chief Executive Officer, RDD Pharma.  “We can now move forward more aggressively in the U.S. to develop RDD-0315 which has the potential to positively impact the health, well-being and quality of life in this patient population.”  Read more.

Source: PRNewswire, September 14, 2017

Florence Italy ICS 2017

GTx Announces Positive Results from Enobosarm Phase 2 Clinical Trial

GTx, Inc. (Nasdaq: GTXI) today announced top-line clinical trial results demonstrating that a daily dose of enobosarm 3 mg (GTx-024) substantially improved stress urinary incontinence (SUI) in women, as well as related quality of life measurements. In this open-label clinical trial, all 17 patients completing 12 weeks of treatment saw a clinically significant reduction (50 percent or greater) in stress leaks per day, compared to baseline. Mean stress leaks decreased by 83 percent from baseline over 12 weeks, and the reductions in daily stress leaks following completion of treatment have been sustained as patients are being followed for up to 7 months post-treatment to assess the durability of treatment effect. No patient has relapsed to her baseline levels. These results were presented at the International Continence Society (ICS) Annual Meeting currently being held in Florence, Italy from September 12-15, 2017. Read more.

Source: Business Wire, September 13, 2017

drugs for overactive bladder (OAB)

Innovus Pharma Launches its Clinically Proven UriVarx™ Product for Bladder Health in the United States

Innovus Pharmaceuticals, Inc. (“Innovus Pharma”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced the launch of UriVarx™ in the U.S. UriVarx™ is clinically proven to reduce urinary urgency, accidents and both day and night frequency in Overactive Bladder (“OAB”) and Urinary Incontinence (“UI”) patients.  Read more.

Source: BusinessWire, December 1, 2016